David Hei, MD
Medical Oncology · Melbourne, FLNPI 1851368476
Payments from drug & device makers
What this record shows
This record is dominated by other: $1,448 of the $2,112 with a category attached, or 68.6%. Novartis accounts for 69.4% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2021 at $1,017 and has fallen 97.5% since, to $25 in 2025. That places this record below the midpoint for medical oncology clinicians in FL, where the typical reported total is $8,890.
Across 51 payments — averaging $41.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$1K
- Johnson & Johnson$215
- Pfizer$55
- Incyte Corporation$43
- Daiichi Sankyo Inc.$35
- Seagen Inc.$29
- plus $269 from 15 others
What the payments were for
- Food & beverage$52825%
- Education$1366%
- Other$1,44869%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 17 | $1,465 |
| Johnson & Johnson | 8 | $215 |
| Pfizer | 3 | $55 |
| Incyte Corporation | 2 | $43 |
| Daiichi Sankyo Inc. | 2 | $35 |
| Seagen Inc. | 2 | $29 |
| AstraZeneca | 2 | $26 |
| E.r. Squibb & Sons, L.L.C. | 2 | $26 |
| Genmab U.S., Inc. | 1 | $25 |
| Hologic Sales And Service, LLC | 1 | $22 |
| Genentech USA, Inc. | 1 | $21 |
| Bristol Myers Squibb | 1 | $18 |
| Lilly USA, LLC | 1 | $18 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $17 |
| AbbVie | 1 | $17 |
| Karyopharm Therapeutics Inc. | 1 | $15 |
| Merck | 1 | $13 |
| GSK | 1 | $13 |
| Taiho Oncology, Inc. | 1 | $13 |
| Eisai Inc. | 1 | $13 |
| Gilead | 1 | $12 |
How this compares
$2,112 in reported general payments places this provider in the 25th percentile of 507 medical oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 33 | $580,247 |
| BrukinsaZanubrutinib | 37 | $535,028 |
| IbrancePalbociclib | 33 | $527,309 |
| PomalystPomalidomide | 23 | $508,521 |
| TasignaNilotinib Hcl | 17 | $330,922 |
| TagrissoOsimertinib Mesylate | 12 | $206,969 |
| KisqaliRibociclib Succinate | 12 | $201,442 |
| JakafiRuxolitinib Phosphate | 11 | $186,873 |
| XtandiEnzalutamide | 13 | $183,926 |
| ImbruvicaIbrutinib | 11 | $169,371 |
| VenclextaVenetoclax | 15 | $92,364 |
| EliquisApixaban | 95 | $82,773 |
| InrebicFedratinib Dihydrochloride | 12 | $80,343 |
| XareltoRivaroxaban | 48 | $50,072 |
| Abiraterone Acetate | 21 | $48,331 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid, Inrebic | $18 | $660,58945 claims |
| PfizerIbrance, Eliquis | $55 | $610,082128 claims |
| NovartisTasigna, Kisqali | $1,465 | $532,36429 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $26 | $508,52123 claims |
| AstraZenecaTagrisso | $26 | $206,96912 claims |
| Incyte CorporationJakafi | $43 | $186,87311 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $17 | $169,37111 claims |
| AbbVieVenclexta | $17 | $92,36415 claims |
| Johnson & JohnsonXarelto | $215 | $50,07248 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 507 medical oncology providers in Florida.
Other medical oncology in Melbourne
- Neil LoveMiami$5.6M
- Mahdi TahaBoca Raton$1.7M
- Raji ShameemOrlando$1.3M
- Mohammad JahanzebBoca Raton$1.3M
- Michel VelezOrlando$927K
- Yuanbin ChenOrlando$810K
- Reshma MahtaniPlantation$608K
- Rebecca MorooseOrlando$543K
- Yasser KhaledOrlando$444K
- Judah FriedmanPalm Beach Gardens$416K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.